Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC

Inclusion Criteria: * Histologically confirmed, unresectable locally advanced (stage IIIB with pleural effusion) or metastatic (stage IV) non-squamous NSCLC * Performance status (WHO) 0-1 * Adequate bone marrow (ANC ≥ 1,500/mm3, PLT ≥ 100,000/mm3, Hgb ≥ 11 g/dL), liver (Bilirubin ≤ 1.5 UNL, SGOT/SGPT ≤ 2.5 UNL, ALP ≤ 5 UNL), and renal function (Creatinine ≤ UNL - if borderline, creatinine clearance should be ≥ 60 mL/min) * No previous chemotherapy or immunotherapy for advanced/metastatic NSCLC is allowed --Previous radiotherapy is allowed provided that the measurable lesions are outside the radiation fields * Measurable disease, defined as at least 1 bidimensionally measurable lesion ≥ 20 X 10 mm * Patient able to take oral medication * Absence of active CNS disease * Paraffin embedded sample of primary or metastatic tumor diagnostic specimen must be available * Patients must be able to understand the nature of this study and give written informed consent Exclusion Criteria: * Pregnant or lactating women * Women of child-bearing age unable or unwilling to take effective contraceptive measures * Active CNS disease, brain metastases, or leptomeningeal involvement * Symptomatic neuropathy \> grade1 according to the NCI CTCAE (version 3.0) * Cardiovascular disease (class II-IV NYHA congestive heart failure, myocardial infarction within the previous 4 months, LVEF \< normal, uncontrolled hypertension, ventricular arrhythmia), anticoagulation treatment or thrombotic event within the previous 6 months * Active infection, requiring IV antibiotic treatment, within the previous 2 weeks * Long-term oxygen therapy * Second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer * Radiotherapy within the previous 4 weeks * Previous radiotherapy to the only measurable lesion * Concurrent treatment with other anti-cancer drug * Uncontrolled hypercalcemia * Known allergy to drugs with similar chemical structure to study drugs. Concurrent corticosteroids, except for chronic therapy with methylprednisolone ≤ 20 mgr daily (or equivalent) for more than one month